LAVA THERAPEUTICS N.V.

(LVTX)
  Rapporto
Tempo differito Nasdaq  -  20/05 21:36:06
3.440 USD   +2.38%
18/05LAVA THERAPEUTICS N.V.: prospettiva positiva di SVB Securities LLC
MM
17/05LAVA Therapeutics N.V. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2022
CI
12/05Lava Therapeutics dice che la FDA ha approvato la domanda IND per Lava-051 per il trattamento della leucemia e di altre malattie; le azioni salgono.
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su LAVA THERAPEUTICS N.V.
17/05LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2..
17/05LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
17/05LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
17/05LAVA Therapeutics N.V. Announces the Resignation of Ed Smith as Chief Financial Officer
12/05Lava Therapeutics Says FDA Clears IND Application for Lava-051 to Treat Leukemia, Other..
12/05LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematol..
12/05LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematol..
12/05Lava Therapeutics N.V. Announces FDA IND Clearance for Lava-051 for the Treatment of He..
05/05LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
05/05LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
27/04LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Societ..
27/04LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Societ..
28/03LAVA THERAPEUTICS N: Provides Business Update and Reports Fourth Quarter and Year End 202..
24/03LAVA Therapeutics Q4 Net Loss Narrows as Revenue Declines
24/03LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021..
24/03LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021..
24/03LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 3..
24/03LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 20..
10/03LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
10/03LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
07/03LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticanc..
07/03LAVA Therapeutics N.V. Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Ant..
01/02LAVA Therapeutics Doses First Patient in Clinical Trial of Potential Prostate Cancer Dr..
01/02LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of ..
01/02LAVA Therapeutics N.V. Announces Dosing of the First Patient in the Phase 1/2A Clinical..
28/01Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthc..
28/01Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthc..
18/01LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Plat..
18/01LAVA Therapeutics N.V. Presents Preclinical Data on its Gammabody™ T Cell Engager ..
2021CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annu..
2021CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annu..
2021LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare C..
2021LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
2021Lava Therapeutics B.V. Reports Earnings Results for the Third Quarter and Nine Months E..
2021LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Sy..
2021LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Sy..
2021LAVA Therapeutics Expands Management Team with Three Key Appointments
2021LAVA Lava Therapeutics Appoints Sumeet Ambarkhane as Executive Medical Director
2021LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Confere..
2021LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
2021Health Care Stocks Easing Slightly in Late Trade
2021Health Care Stocks Advancing With Rising Friday Markets
2021Health Care Stocks Climb Pre-Bell Friday
2021LAVA Therapeutics Gets FDA Orphan Designation for LAVA-051
2021LAVA THERAPEUTICS B: ' Leukemia Drug Candidate Gets FDA's Orphan Drug Designation; Shares..
2021LAVA THERAPEUTICS B: Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment ..
2021LAVA Therapeutics N.V. Receives FDA Orphan Drug Designation for LAVA-051 for the Treatm..
2021Top Premarket Decliners
2021LAVA Therapeutics Up 7% After Orphan Drug Designation
2021CORRECTING AND REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell ..
2021LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment o..
2021Certain Common Shares of LAVA Therapeutics N.V. are subject to a Lock-Up Agreement Endi..
2021Certain Share Options of LAVA Therapeutics N.V. are subject to a Lock-Up Agreement Endi..
2021LAVA THERAPEUTICS B: N.V. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (F..
2021Lava Therapeutics B.V. Anticipates Data from the Phase 1 Dose Escalation Phase of the S..
2021LAVA THERAPEUTICS B: Provides Business Update and Reports Second Quarter Results
2021LAVA Therapeutics N.V. Announces Unaudited Consolidated Earnings Results for the Second..
2021LAVA THERAPEUTICS B: Announces Appointment of Amy Garabedian as General Counsel and Corpo..
2021LAVA Therapeutics N.V Announces Appointment of Amy Garabedian as Corporate Secretary
2021LAVA THERAPEUTICS B: Doses First Patient in Study of Potential Cancer Drug
2021LAVA THERAPEUTICS B: Announces Treatment of First Patient in Phase 1/2a Clinical Trial of..
2021LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of ..
2021LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference
2021LAVA THERAPEUTICS B: Unaudited Condensed Consolidated Interim Financial Statements as of ..
2021LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
2021LAVA Therapeutics N.V. Reports Earnings Results for the Three Months Ended March 31, 20..
2021LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
2021LAVA THERAPEUTICS B: Appoints Karen J. Wilson to its Board of Directors
2021Lava Therapeutics B.V. Appoints Karen J. Wilson to its Board of Directors and as Chair ..
2021LAVA THERAPEUTICS B.V.(NASDAQGS: LVTX) added to NASDAQ Composite Index
2021LAVA Therapeutics N.V. has completed an IPO in the amount of $100.5 million.
2021LAVA Therapeutics B.V. Appoints Edward F. Smith as Chief Financial Officer
2021LAVA Therapeutics N.V. has filed an IPO in the amount of $100 million.
2021Lava Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors
2020LAVA Therapeutics Announces $83 Million Series C Financing to Advance Novel Immuno-Onco..
1  2Pross.
Prossimo evento su LAVA THERAPEUTICS N.V.